Physician profile
Cicily Jones
NPI 1255396511
$7,792.00
in general payments reported to CMS, 2019-2025
36 companies · $2,619 in 2025
The $2,619 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $385 · 2020: $825 · 2021: $675 · 2022: $619 · 2023: $1,144 · 2024: $1,526 · 2025: $2,619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,268 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,268.05 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,757.18 | 2019-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $1,661.41 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $489.60 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $462.84 | 2019-2025 | Jardiance, Synjardy |
| Abbvie INC. | $452.55 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $435.26 | 2021-2025 | |
| Glaxosmithkline, LLC. | $323.08 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Kowa Pharmaceuticals America, INC. | $248.52 | 2024-2025 | Zoryve |
| Amgen INC. | $231.59 | 2019-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $177.09 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $153.76 | 2023-2025 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $125.10 | 2024-2025 | Voquezna |
| Astellas Pharma US INC | $123.96 | 2019-2023 | Myrbetriq |
| E.R. Squibb & Sons, L.L.C. | $117.82 | 2019-2025 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $110.25 | 2019-2024 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cicily Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.